Slashdot Mirror


Biology Goes Open Source

cford writes "According to Forbes some of the drug company giants are finally realizing that their genetic research is worth more if they give it away. 'Novartis, the Basel, Switzerland, drug giant, has helped uncover which of the 20,000 genes identified by the Human Genome Project are likely to be associated with diabetes. But rather than hoard this information, as drug firms have traditionally done, it is making it available for free on the World Wide Web. "It will take the entire world to interpret these data," says Novartis research head Mark Fishman. "We figure we will benefit more by having a lot of companies look at these data than by holding it secret."'"

10 of 100 comments (clear)

  1. How long until legal problems manifest themselves? by SpaceLifeForm · · Score: 4, Insightful

    It just seems unlikely that the darkside won't
    come up with some 'problem' to squash this
    wonderful idea.

    --
    You are being MICROattacked, from various angles, in a SOFT manner.
  2. Biological Stallman by shawn443 · · Score: 5, Insightful

    But another requirement of making the leap from genes to drugs is making the research public--a step that will make it difficult for researchers elsewhere to patent any of this raw genetic information. The only thing I hate worse than software patents are genetic patents. If any industries could use a Stallman it would be biotech and genetic.
  3. Mainly a good PR move . . . by cashman73 · · Score: 5, Insightful
    It's not like Novartis has made their entire drug database public with all of their notes regarding which drugs they're interested in pursuing or not,... They've done some significant analysis into the diabetes gene, and rather than withholding it, they're making it public. There's no real compelling reason to protect this aspect of the research, so why not? The benefits of releasing it outweigh the negatives:

    • They still get to do their own research and develop their own drugs to target specific genes in this area.
    • They get huge kudos in the PR arena for their attempts at finding a cure for cancer diabetes. They can use this in advertising campaigns.
    • As researchers in other pharmaceutical companies and/or academia use this information, they'll eventually write grants and use it in their research. Novartis will still get the advantage from them citing the source,... Again, see the above advertising part,...
  4. Yeah, but... by guruevi · · Score: 4, Insightful

    closed source is so much more secure... what we need is developers, developers, developers, yeah, whoo

    Seriously, I think all findings on the human genome project should be open. It took a huge effort and even persons at home let spare cycles run on this project. Our bodies, and what's inside should be open since it's not something 'they' invented, manufactured or engineered. Whatever drugs they're developing could be closed, but generics should definitely be allowed too.

    --
    Custom electronics and digital signage for your business: www.evcircuits.com
  5. A step in the right direction by nickv111 · · Score: 5, Informative

    Patents on the medical and biological industry, while potentially good for the companies, are truly terrible for the rest of the world. The last thing we need is more expensive medicine, and having biological trade secrets released will help humanity as a whole.

    I've done a little research on AIDS, for example, and to give you an example of what patents do for the cost of medicine, take a look at this quote from the New York Times article, "Look at Brazil."

    "Until a year ago, the triple therapy that has made AIDS a manageable disease in wealthy nations was considered realistic only for those who could afford to pay $10,000 to $15,000 a year or lived in societies that could."

    In developing countries, the cost of patented medication is the reason why many families cannot afford it and so many suffer from it. Now look at another quote from the same article:

    "Brazil now produces some triple therapy for $3,000 a year and expects to do much better, and the price could potentially drop to $700 a year or even less."

    Many countries cannot do this for fear of economic sanctions, which means the next logical step would be for companies to open up their medical and biological information, for the good of humanity. Not only will this help potential consumers of this medication, but also provide a base for other companies to build on to excel each other's knowledge.

    1. Re:A step in the right direction by Dunbal · · Score: 4, Insightful

      So, in fact, the pharama company has to make $900,000,000 in PROFIT, each year for 10 years, just to make up for the cost of getting FDA approval.

            You know, drug companies don't suddenly stop making profit once the patent expires and competition begins. Look at how many companies sell plain old acetyl-salicilate (aka aspirin). They're obviously making money. So that's the first hole in your argument right there.

            Secondly, drug companies seem to forget that not everyone has a US income level. The price of medication is the same or more expensive outside the US than inside. This is to prevent people from "smuggling" meds into the US that were bought cheaper elsewhere. God forbid! So instead of getting into a 20 times bigger WORLD market, they decide to produce less, at a higher price. North americans can afford it - barely. And only the upper class everywhere else. And the rest, well, they just die younger. Who cares, right?

            Oh and as a doctor I've been invited to many, MANY dinners - at 5 star hotels, by pharmaceutical companies. I've had friends who have been flown to exotic locations for conferences on behalf of pharmaceutical companies. They want to give me lots of promotional things, from notepads to calculators and clocks, trying to recruit me as a salesman - they think my prescription pad is for hire. This costs money too.

            If only they understood that although I might read about the new wonderdrug in medical journals, what I usually prescribe is the cheapest medication around. It's what my patients want. I always give them a choice - the latest thing is X, the cheapest is Y. Invariably they choose Y.

            Big pharma should get that in their heads. The old products that they are still selling, even without patents, is what should fund the research. Someone who has taken lipitor for the past 10 years and is happy with it is probably not going to change in the NEXT 10 years.

            They should not gouge people on a new med because a) they can, due to a monopoly situation and b) try to justify this gouging because of "the cost of research".

            But then again, pharmacology has always been about commerce and making money. Healing the patient is incidental.

      --
      Seven puppies were harmed during the making of this post.
  6. Re:Speaking of which.. by Pedrito · · Score: 4, Funny

    Any of you 3 Womans on slashdot wanna give away some genetic research?

    http://en.wikipedia.org/wiki/Woman


    Clearly you went straight to the naked pictures and skipped the second sentence of the article you link that points out that the plural of "woman" is "women" and not "Womans". Not that the post would have been funny if you could spell.

  7. I call BS by cinnamon+colbert · · Score: 4, Interesting

    What this means is they can't figure out how to use the info before the patents expire. The idea that novartis or any other drug company would let loose proprietary info on a gene they thought would lead them to a drug for diabetes is ludicrous.

  8. Re:What do you know by MightyMartian · · Score: 5, Insightful

    While I applaud the company, the notion that the human genome or any part of it is anyone's to keep, license or give away is appalling.

    --
    The world's burning. Moped Jesus spotted on I50. Details at 11.
  9. Biology was already open source by Puff+Daddy · · Score: 4, Insightful

    The study of biology was already open source. There is a wealth of data at the NCBI and other sources. We are seeing a renaissance in molecular biology right now and I, for one, attribute it to the hard work of thousands of researchers freely sharing their work. It's not just the data either, it's journals and software, too. We have more information than we know how to handle, and it's being created much faster than it will ever be understood. It's gotten to a point where new fields of study are being created just to interpret the collected data and try to make some sense of it. Bioinformatics and computational biology are truly amazing fields, the only trouble is attempting to explain just what it is you do to friends and relatives. Trust me, it's not always easy.